POS1378 COMPARISON OF DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS AND PATIENTS WITH AXIAL SPONDYLOARTHRITIS ACCOMPANYING FAMILIAL MEDITERRANEAN FEVER

Background: The rate of co-occurrence Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA) in adults is reported ranging from 0.5% to 7.5%. clinical implications this the course FMF still a research question. Objectives: To compare demographic features patients with FMF+axSpA. Methods: A total 9630 was detected according ICD-10 code (E85.0) Hacettepe University Hospital database. 241 these also had axSpA (M45). diagnosis confirmed by Tel-Hashomer criteria. AxSpA either presence sacroiliitis on sacroiliac radiography Modified New York Criteria (mNY) or active ASAS criteria magnetic resonance imaging. 136 were criterias as having As control group, 231 consequent without recorded “FMF Central Anatolia (FiCA) database” followed up at our center included analysis. Demographic those both groups compared. p<0.05 considered statistically significant, correction for multiple comparisons not performed. Results: FMF+axSpA group group. 114 (83.8%) radiographic mNY criteria; median cervical mSASSS 0 (available 49 patients, min-max, 0-36), lumber 4 121 33 (27%) syndesmophyte. Twenty-six (19.1%) radiologically documented inflammatory hip disease 12 (8.8%) underwent replacement. Female gender more prevalent (53.7% vs 32.5%, p<0.001). Age symptom onset earlier patients; however, durations longer study cohort (Table 1). Frequency signs symptoms comparable except pleuritis higher compared (p=0.003). Amyloidosis (6.6% vs. 1.7%, p=0.014). Results MEFV gene analysis available 273 patients. Although M694V mutation (either 1 allele 2 alleles) groups, homozygous (39.8% 28.9%, p=0.02). Conclusion: coexistence appears be associated increased prevalence amyloidosis. burden second may explain risk. Table 1. Comparison two groups. FMF+AxSpA (n=136, 37.1% ) (n=231, 62.9% p Female, n(% 73 (53.7) 75 (32.5) <0.001 onset, years med (IQR (5-20) 10 (6-18) 0.046 Symptom duration, years, 24 (18-32) 20 (14-29) 0.007 diagnosis, (13-33) (11-30) 0.10 Duration after 16 (10-22) 13 (7-17) symptoms, -Fever 128 (94.1) 204 (88.3) 0.067 -Abdominal pain 123 (90.4) 217 (93.9) 0.21 -Pleuritis 31 (22.8) 87 (37.7) 0.003 -Pericarditis 3 (2.2) (1.0) 0.34 -Arthritis 64 (47.1) 92 (39.8) 0.17 -Erysipelas (17.6) 38 (16.5) 0.77 -Febrile myalgia 9 (6.6) (5.6) 0.70 Inflammatory back pain, (67.6) 26 (11.3) bowel disease, 6 (4.4) (1.7) 0.12 family history, -Any degree 66 (48.5) 137 (59.8) 0.04 -First 48 (35.8) 97 (42.0) 0.24 -Second 25 (18.7) 86 (37.2) Number attacks recent year, (min-max (0-12) (0-10) 0.13 0.014 status (N=273 -Present (one allels 91 (80.5) 120 (75.0) 0.28 -Two 45 43 (28.9) 0.02 Disclosure Interests: None declared